drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
Rabbit polyclonal anti-thymocyte globulin (polyclonal IgG) given as a single IV dose (1 mg/kg) 48–72 hours after emergence from aplasia to reinforce GVHD prophylaxis after haploidentical allo-HSCT. Binds multiple T‑cell surface antigens (e.g., CD2, CD3, CD4, CD8, HLA‑DR) leading to T‑cell depletion via complement-dependent cytotoxicity and apoptosis, with Fc-mediated clearance and immunomodulatory effects; also impacts B cells, NK cells, and dendritic cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antithymocyte Globulin
drug_category
CYTOTOXIC ANTIBODY
drug_class
Cytotoxic protein
drug_delivery_route
Intravenous
drug_mechanism_of_action
Rabbit polyclonal IgG that binds multiple T‑cell surface antigens (e.g., CD2, CD3, CD4, CD8, HLA‑DR), causing T‑cell depletion via complement‑dependent cytotoxicity and apoptosis, with Fc‑mediated clearance (ADCC/ADCP) and immunomodulatory effects; also impacts B cells, NK cells, and dendritic cells to reduce alloreactivity and GVHD risk.
drug_name
Thymoglobulin (rabbit anti-thymocyte globulin)
nct_id_drug_ref
NCT06066255